Netherlands-based AM-Pharma BV has raised new capital of €47 million, enabling it to start plans for a pivotal Phase 3 trial of its therapy for acute kidney injury, a disease with a high mortality rate and no approved pharmacological treatments. The newest financing, which involves a commitment from Cowen Healthcare Investments, brings total proceeds for the Phase 3 programme to €163 million, which will also support preparations for registration. The company intends to enrol 1,400 patients with sepsis-associated acute kidney injury in the trial with sites across 12 countries.
